ORPHA:889
Cutaneous small vessel vasculitis
Also known as: Cutaneous hypersensitivity vasculitis
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
1,185
Trials
0
Interventional, condition-specific
Researchers
947
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A small vessel vasculitis characterized by neutrophilic inflammation predominantly limited to the superficial cutaneous postcapillary venules and without systemic vasculitis or glomerulonephritis. Typical presentation is of unifocal or multifocal palpable purpura on the lower extremities.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019509
- UMLS:C4049638
- NCIT:C122919
Additional Mondo synonyms (5)
cutaneous hypersensitivity vasculitis · cutaneous leukocytoclastic vasculitis · cutaneous small vessel vasculitis · cutaneous small-vessel vasculitis · hypersensitivity angiitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,185 matched papers (688 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 195 for broader category vasculitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,185
1,185 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,185 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
688 in the last 10 years · low confidence
Phrase hits: 1,185 · MeSH hits: 0
Who's working on it?
947
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Micheletti RG4 papers · 2026
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Papers in Europe PMC - 02Agrawal I3 papers · 2025
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, India.
Papers in Europe PMC - 03Maronese CA3 papers · 2026
Department of Dermatology, Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 04Marzano AV3 papers · 2026
Department of Dermatology, Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 05Yamamoto T3 papers · 2026
Department of Dermatology, Fukushima Medical University, Fukushima. toyamade@fmu.ac.jp.
Papers in Europe PMC - 06Ajao A2 papers · 2022
Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Papers in Europe PMC - 07Alpsoy E2 papers · 2026
Department of Dermatology, Akdeniz University, Antalya, Turkey.
Papers in Europe PMC - 08Antony MA2 papers · 2025
Department of Endocrinology, Diabetes and Nutrition, Medical University of South Carolina-AnMed Clinical Campus, Anderson, SC, USA.
Papers in Europe PMC - 09Caproni M2 papers · 2026
Department of Health Sciences, Rare Diseases Unit, Azienda USL Toscana Centro, Section of Dermatology, University of Florence, European Reference Network Skin Member, Florence, Italy.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 195 trials are registered for vasculitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
195 interventional trials matched vasculitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: vasculitis
195
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07388277·RECRUITING·CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis·Matched via name phrase
- NCT06277427·RECRUITING·Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Conditions: Lupus Nephritis · ANCA Associated Vasculitis·Matched via name phrase
- NCT07448454·NOT YET RECRUITING·Role of Vessel Wall MRI in Differentiaition Between Intracranial Atherosclerotic Disease and Vasculitis as Causes of Ischemic Stroke
Conditions: Intracranial Atherosclerotic Disease (ICAD) and Vasculitis·Matched via name phrase
- NCT07268521·NOT YET RECRUITING·A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
Conditions: Cryoglobulinemic Vasculitis (CV)·Matched via name phrase
- NCT07315087·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Conditions: SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06986018·NOT YET RECRUITING·Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
Conditions: Idiopathic Inflammatory Myopathies · ANCA-Associated Vasculitis·Matched via name phrase
- NCT06980597·RECRUITING·A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06821659·NOT YET RECRUITING·Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erthematosus · Systemic Sclerosis (SSc) · Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06868290·RECRUITING·Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06335888·RECRUITING·A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT07246096·RECRUITING·Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Conditions: Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Sclerosis · Primary Sjögren Syndrome·Matched via name phrase
- NCT06611696·RECRUITING·Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT07339540·RECRUITING·the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Conditions: Recurrent or Refractory Systemic Lupus Erythematosus · Recurrent or Refractory IgG4 Related Diseases · Recurrent or Refractory Systemic Sclerosis · Recurrent or Refractory Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT03290456·RECRUITING·Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Conditions: Granulomatosis With Polyangitis·Matched via name phrase
- NCT07236801·RECRUITING·Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Sjogren's Syndrome (SS) · Inflammatory Myopathy·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cutaneous small vessel vasculitis" OR "Cutaneous hypersensitivity vasculitis" OR "cutaneous leukocytoclastic vasculitis" OR "cutaneous small-vessel vasculitis" OR "hypersensitivity angiitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cutaneous small vessel vasculitis" OR "Cutaneous hypersensitivity vasculitis" OR "cutaneous leukocytoclastic vasculitis" OR "cutaneous small-vessel vasculitis" OR "hypersensitivity angiitis" OR "immune complex mediated vasculitis"
Recall-expansion terms: immune complex mediated vasculitis
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"vasculitis"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1185) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T15:46:40.507Z
